Cytosorbents Corporation

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Investigation Details

On December 28, 2023, Cytosorbents issued a press release announcing that its pivotal trial investigating the ability of its device candidate, DrugSorb®-ATR, to reduce perioperative bleeding in patients on ticagrelor (Brilinta®, Brilique® – AstraZeneca) undergoing cardiothoracic surgery before completing the recommended washout period, “did not meet the primary effectiveness endpoint in the overall patient population that underwent different types of cardiac surgeries.”

On this news, Cytosorbents’ stock price fell $0.545 per share, or 33.44%, to close at $1.085 per share on December 28, 2023.